NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antivirals, has announced promising results for its lead drug candidate, NV-387, in treating measles. In a study using humanized mice, NV-387 demonstrated a 130% increase in survival rates, from 7.4 to 17 days, with no observed toxicity and dose-dependent efficacy. This breakthrough comes at a critical time as global measles cases surge and vaccine coverage declines, underscoring the urgent need for effective therapeutic options.
The drug works by mimicking human cell features to bind and neutralize viruses, targeting over 90% of human pathogens. Anil R. Diwan, PhD, highlighted the significance of NV-387, stating it is on its way to becoming the first drug to treat measles. With plans to advance NV-387 into Phase II human clinical trials, NanoViricides is at the forefront of addressing a pressing global health challenge.
For more information on the study, visit https://ibn.fm/0nUwO.
